Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;44(4):274-9.
doi: 10.1002/dc.23433. Epub 2016 Jan 22.

HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens

Affiliations

HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens

Rieko Nishimura et al. Diagn Cytopathol. 2016 Apr.

Abstract

Background: Human epidermal growth factor receptor 2 (HER2) testing of samples from recurrent or metastatic breast cancer is recommended by the 2013 update of the American Society of Clinical Oncology/College of American Pathologists guidelines. Although cytological analysis can be applied to several types of metastatic lesions, the practical method for HER2 testing of cytological specimens is yet to be resolved. We conducted immunohistochemical (IHC) staining for HER2 in breast cancer cell blocks (CBs) and compared the results with those from the corresponding histological specimens. In cases of discrepancy between the two types of specimen, the bright-field HER2 dual in situ hybridization (DISH) assay was performed.

Methods: CBs were prepared from 54 surgically excised breast cancers. The cells were fixed in 10% buffered formalin and embedded in paraffin. A Ventana BenchMark ULTRA (Roche Diagnostics) with anti-HER-2/neu (4B5) rabbit monoclonal primary antibody and INFORM HER2/neu Dual ISH DNA Probe Cocktail was used for the assays.

Results: Successful results were obtained in 52 of 54 CBs. Forty cases showed agreement between CBs and the histological specimens. No discrepancy was observed between the two types of specimens in cases where HER2 expression was positive. IHC results of CB in 12 discrepant cases were HER2 intermediate or negative. The DISH results of 11 of these cases were negative.

Conclusion: IHC staining of HER2 for breast cancer CBs can be used in the same way as that used for histological specimens, although the number of equivocal cases in CBs is greater than that in histological specimens. Diagn. Cytopathol. 2016;44:274-279. © 2016 The Authors Diagnostic Cytopathology Published by Wiley Periodicals, Inc.

Keywords: DISH; HER2; breast cancer; cell block; immunohistochemistry.

PubMed Disclaimer

Figures

Figure 1
Figure 1
An example of a HER2 negative (1+) case showing consistent results between the CB (a) and histological specimen (b). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 2
Figure 2
An example of a HER2 positive (3+) case showing consistent results between the CB (a) and histological specimen (b). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
Figure 3
Figure 3
An example of a discrepant case of HER2 expression, showing HER2 intermediate (2+) in the CB (a) and HER2 negative (1+) in the histological specimen (b). The results by DISH assay in both CB (c) and histology are negative (d). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Similar articles

Cited by

References

    1. Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31:3997–4013. - PubMed
    1. Monaco SE, Wu Y, Teot LA Cai G. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas. Diagn Cytopathol 2013;41:308–315. - PubMed
    1. Shabaik A, Lin G, Peterson M, et al. Reliability of Her2/neu, estrogen receptor, and progestrone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients with primary and metastatic breast carcinoma. Diagn Cytopathol 2011;39:328–332. - PubMed
    1. Bofin AM, Ytterhus B, Martin C, O'Leary JJ Hagmar BM. Detection and quantitation of HER‐2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110–119. - PubMed
    1. Beatty BG, Bryant R, Wang W, et al. HER‐2/neu detection in fine‐needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis. Am J Clin Pathol 2004;122:246–255. - PubMed

Publication types